There are over 290 million people in China with cardiovascular disease and more than 100 million with chronic kidney disease. Cardiorenal disease is the leading cause of death in China today.
Cardiovascular
Mavacamten is a first-in-class small molecule therapeutic that reversibly binds to myosin to directly target the excess contractility and impaired relaxation underlying hypertrophic cardiomyopathy, or HCM.